Overview

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

Status:
Completed

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Remdesivir